These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 32617743)

  • 21. Current treatment options for meningioma.
    Apra C; Peyre M; Kalamarides M
    Expert Rev Neurother; 2018 Mar; 18(3):241-249. PubMed ID: 29338455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system.
    Yuzawa S; Nishihara H; Yamaguchi S; Mohri H; Wang L; Kimura T; Tsuda M; Tanino M; Kobayashi H; Terasaka S; Houkin K; Sato N; Tanaka S
    Mod Pathol; 2016 Jul; 29(7):708-16. PubMed ID: 27102344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Classification of meningiomas-advances and controversies.
    Harter PN; Braun Y; Plate KH
    Chin Clin Oncol; 2017 Jul; 6(Suppl 1):S2. PubMed ID: 28595423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation between natural history and multi-omics profiling of meningiomas in NF2-related schwannomatosis suggests role of methylation group and immune microenvironment in tumor growth rate.
    Teranishi Y; Yurchenko A; Tran S; Sievers P; Rajabi F; Ruchith S; Abi-Jaoude S; Blouin A; Bielle F; Cazals-Hatem D; Sahm F; Nikolaev S; Kalamarides M; Peyre M
    Acta Neuropathol; 2024 Aug; 148(1):30. PubMed ID: 39192083
    [No Abstract]   [Full Text] [Related]  

  • 25. Histological classification and molecular genetics of meningiomas.
    Riemenschneider MJ; Perry A; Reifenberger G
    Lancet Neurol; 2006 Dec; 5(12):1045-54. PubMed ID: 17110285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical implications of DNA methylation-based integrated classification of histologically defined grade 2 meningiomas.
    Ehret F; Perez E; Teichmann D; Meier S; Geiler C; Zeus C; Franke H; Roohani S; Wasilewski D; Onken J; Vajkoczy P; Schweizer L; Kaul D; Capper D
    Acta Neuropathol Commun; 2024 May; 12(1):74. PubMed ID: 38720399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities.
    Choudhury A; Magill ST; Eaton CD; Prager BC; Chen WC; Cady MA; Seo K; Lucas CG; Casey-Clyde TJ; Vasudevan HN; Liu SJ; Villanueva-Meyer JE; Lam TC; Pu JK; Li LF; Leung GK; Swaney DL; Zhang MY; Chan JW; Qiu Z; Martin MV; Susko MS; Braunstein SE; Bush NAO; Schulte JD; Butowski N; Sneed PK; Berger MS; Krogan NJ; Perry A; Phillips JJ; Solomon DA; Costello JF; McDermott MW; Rich JN; Raleigh DR
    Nat Genet; 2022 May; 54(5):649-659. PubMed ID: 35534562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation.
    Peyre M; Stemmer-Rachamimov A; Clermont-Taranchon E; Quentin S; El-Taraya N; Walczak C; Volk A; Niwa-Kawakita M; Karboul N; Giovannini M; Kalamarides M
    Oncogene; 2013 Sep; 32(36):4264-72. PubMed ID: 23045274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.
    Katz LM; Hielscher T; Liechty B; Silverman J; Zagzag D; Sen R; Wu P; Golfinos JG; Reuss D; Neidert MC; Wirsching HG; Baumgarten P; Herold-Mende C; Wick W; Harter PN; Weller M; von Deimling A; Snuderl M; Sen C; Sahm F
    Acta Neuropathol; 2018 Jun; 135(6):955-963. PubMed ID: 29627952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole-genome sequencing identifies new genetic alterations in meningiomas.
    Tang M; Wei H; Han L; Deng J; Wang Y; Yang M; Tang Y; Guo G; Zhou L; Tong A
    Oncotarget; 2017 Mar; 8(10):17070-17080. PubMed ID: 28177878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Innovative treatments for meningiomas.
    Graillon T; Tabouret E; Salgues B; Horowitz T; Padovani L; Appay R; Farah K; Dufour H; Régis J; Guedj E; Barlier A; Chinot O
    Rev Neurol (Paris); 2023 Jun; 179(5):449-463. PubMed ID: 36959063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
    Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
    J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meningioma pathology, genetics, and biology.
    Lamszus K
    J Neuropathol Exp Neurol; 2004 Apr; 63(4):275-86. PubMed ID: 15099018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
    BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments.
    Choy W; Kim W; Nagasawa D; Stramotas S; Yew A; Gopen Q; Parsa AT; Yang I
    Neurosurg Focus; 2011 May; 30(5):E6. PubMed ID: 21529177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
    Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
    Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular genetics of meningiomas: from basic research to potential clinical applications.
    Simon M; Boström JP; Hartmann C
    Neurosurgery; 2007 May; 60(5):787-98; discussion 787-98. PubMed ID: 17460514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathodiagnostic parameters and evaluation of O⁶- methyl guanine methyl transferase gene promoter methylation in meningiomas.
    Jabini R; Moradi A; Afsharnezhad S; Ayatollahi H; Behravan J; Raziee HR; Mosaffa F
    Gene; 2014 Apr; 538(2):348-53. PubMed ID: 24398011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas.
    Clark VE; Harmancı AS; Bai H; Youngblood MW; Lee TI; Baranoski JF; Ercan-Sencicek AG; Abraham BJ; Weintraub AS; Hnisz D; Simon M; Krischek B; Erson-Omay EZ; Henegariu O; Carrión-Grant G; Mishra-Gorur K; Durán D; Goldmann JE; Schramm J; Goldbrunner R; Piepmeier JM; Vortmeyer AO; Günel JM; Bilgüvar K; Yasuno K; Young RA; Günel M
    Nat Genet; 2016 Oct; 48(10):1253-9. PubMed ID: 27548314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biology and clinical management challenges in meningioma.
    Mawrin C; Chung C; Preusser M
    Am Soc Clin Oncol Educ Book; 2015; ():e106-15. PubMed ID: 25993161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.